Science Explorer Interactive view Map
Hospital / health system · East Melbourne · Australia

Australasian Leukaemia and Lymphoma Group

allg.org.auROR OpenAlex
Research works
41
▲ 52% vs 2013–17
Citations
1.2k
29.6 per fractional work
Top-10% rate
21.7%
record average 16.5%
Open access
32%
world 28%

Not ranked overall: Australasian Leukaemia and Lymphoma Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 1.61× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 0.99× its world share, 0 worksImmunology and Micro…Chemistry: 0.07× its world share, 0 worksChemistryEarth and Planetary Sciences: 1.95× its world share, 0 worksEarth and Planetary …Engineering: 0.08× its world share, 0 worksEngineeringEnvironmental Science: 1.12× its world share, 0 worksEnvironmental ScienceMathematics: 0.70× its world share, 0 worksMathematicsPhysics and Astronomy: 0.03× its world share, 0 worksPhysics and AstronomyMedicine: 4.03× its world share, 6 worksMedicineNursing: 2.10× its world share, 0 worksNursingSocial Sciences: 0.07× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.0×. Every wedge is a field page.

Which keywords describe research at Australasian Leukaemia and Lymphoma Group?

By fractional works in all years, weighted toward what it does more of than the world: Prognostic Factors, Rituximab, Therapeutic Targets, Chronic Lymphocytic Leukemia, Genomic Aberrations, Classification, Lymphoma and Mutation.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 35 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 35 words, with their numbers
  1. Prognostic Factors10▲ 56×8 topics
  2. Rituximab10▲ 151×3 topics
  3. Therapeutic Targets6▲ 61×2 topics
  4. Chronic Lymphocytic Leukemia6▲ 294×1 topic
  5. Genomic Aberrations6▲ 294×1 topic
  6. Classification5▲ 35×2 topics
  7. Lymphoma5▲ 81×3 topics
  8. Mutation4▲ 71×3 topics
  9. BCR-ABL4▲ 390×1 topic
  10. Imatinib4▲ 390×1 topic
  11. PET Imaging4▲ 46×4 topics
  12. Genetic Pathogenesis4▲ 161×1 topic
  13. Molecular Profiling4▲ 81×1 topic
  14. Minimal Residual Disease3▲ 121×2 topics
  15. Acute Lymphoblastic Leukemia3▲ 197×1 topic
  16. Childhood Cancer3▲ 197×1 topic
  17. Chemotherapy2▲ 5.1×12 topics
  18. Hematopoietic Stem Cells2▲ 36×2 topics
  19. AML1▲ 66×1 topic
  20. Acute Myeloid Leukemia1▲ 66×1 topic
  21. Imatinib Mesylate1▲ 56×2 topics
  22. Fusion Genes1▲ 109×1 topic
  23. Hypereosinophilic Syndrome1▲ 109×1 topic
  24. Climate Change1◆ 1.01×13 topics
  25. Genetic Diversity1▲ 5.5×2 topics
  26. Immunotherapy1▲ 4.1×3 topics
  27. Invasive Species1▲ 4.5×3 topics
  28. Prognostic Scoring System1▲ 74×2 topics
  29. Ageing Population1▲ 63×1 topic
  30. Chicken Domestication1▲ 161×1 topic
  31. Health Care Expenditure1▲ 63×1 topic
  32. Illegal Wildlife Trade1▲ 218×1 topic
  33. Leukemia1▲ 37×2 topics
  34. Parrot Poaching1▲ 218×1 topic
  35. Village Poultry1▲ 161×1 topic

Which research topics does Australasian Leukaemia and Lymphoma Group publish most on?

By volume in 2022–2025: Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research and Lymphoma Diagnosis and Treatment.

Chronic Lymphocytic Leuk…1Chronic Lymphocytic Leukemia Research: 1 fractional worksChronic Myeloid Leukemia Treatments: 1 fractional worksAcute Lymphoblastic Leukemia research: 1 fractional worksLymphoma Diagnosis and T…1Lymphoma Diagnosis and Treatment: 1 fractional worksAcute Myeloid Leukemia R…0Acute Myeloid Leukemia Research: 0 fractional worksEosinophilic Disorders and Syndromes: 0 fractional worksMyeloproliferative Neoplasms: Diagnosis and Treatment: 0 fractional worksMultiple Myeloma Research and Treatments: 0 fractional worksAeolian processes and effects: 0 fractional worksCAR-T cell therapy research: 0 fractional works
GeneticsHematologyPublic Health, Environmental and Occupational HealthPathology and Forensic Medicine3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chronic Lymphocytic Leukemia Research Genetics 1 works
  2. 2 Chronic Myeloid Leukemia Treatments Hematology 1 works
  3. 3 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 1 works
  4. 4 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
  5. 5 Acute Myeloid Leukemia Research Hematology 0 works
  6. 6 Eosinophilic Disorders and Syndromes Rheumatology 0 works
  7. 7 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 0 works
  8. 8 Multiple Myeloma Research and Treatments Hematology 0 works
  9. 9 Aeolian processes and effects Earth-Surface Processes 0 works
  10. 10 CAR-T cell therapy research Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available32.0%not open68.0%

World: 28% of research is openly available.

with international co-authors28.1%domestic only71.9%

World: 19% is written across borders.

How has Australasian Leukaemia and Lymphoma Group's research output changed?

Output in 2018–2022 was 52% higher than in 2013–2017.

199520002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in East Melbourne

All research institutions in East Melbourne

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.